One of the most common reasons people seek medical care is when they experience pain, and this can be acute or chronic [1]. Acute pain has a sudden onset, is of short duration, and is clearly associated with a cause, whereas chronic pain has been defined as pain that lasts or recurs for longer than 3 months [2]. Note that this definition includes pain with an unknown origin. Chronic pain persists beyond normal healing and represents a major public health challenge [3].
In recent years, the plant-derived substance kratom (from Mitragyna speciosa) has gained attention among people seeking alternatives to conventional pain medications. While kratom is not an approved medical treatment, survey data suggest it is frequently used by people experiencing ongoing pain conditions [4].
Understanding where kratom is most often used requires an understanding of the biological differences between acute and chronic pain, current standards of care, and what the scientific literature says about kratom’s pharmacology, risks, and reported patterns of use, which leads us into this article.
Defining Acute and Chronic Pain
Acute pain is the body’s immediate response to injury, inflammation, or tissue damage, and virtually all of us have experienced this. It serves a protective function by telling us that something is wrong. It typically has a sudden onset, is of short duration, and tends to resolve as healing takes place. Examples of this include pain following a surgery, fractures, burns, infections, or tooth pain. Treatment for acute pain seeks to address the underlying cause(s) and provide short-term relief through stabilization, rest, and pain medication (which could include short-term opioid therapy, if appropriate).
Conversely, chronic pain is typically defined as pain lasting longer than 12 weeks or beyond the expected period of tissue healing. Unlike acute pain, chronic pain may persist even after the original injury has resolved. This pain is linked with sleep disturbance, depression, and impaired quality of life, and takes the form of chronic low back pain, fibromyalgia, migraine, and neuropathic pain, among others.
Chronic pain involves neuroplastic changes in the central and peripheral nervous systems. Over time, pain signaling pathways may become hypersensitive, making treatment more complex than simply reducing inflammation.
Management often requires a multimodal approach, comprising physical therapy, cognitive behavioral therapy, exercise rehabilitation, certain antidepressants or anticonvulsants, and carefully monitored opioid therapy in select instances [5].
What Is Kratom?
Kratom is derived from the leaves of Mitragyna speciosa, a tree native to Southeast Asia. Its primary alkaloids (mitragynine and 7-hydroxymitragynine) interact with opioid receptors in the brain, particularly the μ-opioid receptor [6–9].
Unlike prescription opioids, kratom products are not FDA-approved for any medical use, vary widely in potency and purity, are sold in various forms, and are subject to inconsistent regulation depending on jurisdiction [10,11].
Pharmacological Rationale for Kratom Use in Acute and Chronic Pain
Kratom’s alkaloids exhibit partial agonist activity at opioid receptors. Laboratory and animal studies suggest these compounds may produce analgesic effects through similar mechanisms to opioids, though their signaling profile differs somewhat [12].
Because chronic pain often involves central sensitization and altered opioid signaling pathways, substances that interact with opioid receptors may bring about subjective relief. This pharmacological interaction partly explains why kratom is reported as being used for persistent pain conditions.
However, mechanistic plausibility does not equate to proven clinical efficacy. To date, high-quality randomized controlled trials evaluating kratom for either acute or chronic pain are lacking in humans [13].
Patterns of Kratom Use for Pain
There is limited evidence suggesting widespread kratom use specifically for short-term acute injuries or postoperative pain. Acute pain management typically involves readily available over-the-counter medications, short courses of prescription analgesics, and, importantly, medical supervision as required.
As acute pain often resolves within days or weeks, individuals are less likely to seek alternative long-term substances. What’s more, the unpredictability of kratom’s potency and onset may make it less suitable for acute clinical scenarios, where dosing precision is critical.
Survey-based studies suggest that chronic pain is one of the most commonly reported reasons for kratom use in the United States [4,13,14].
In a large survey study, many respondents indicated using kratom to manage ongoing pain conditions such as back pain, arthritis, and neuropathic pain [15]. Other observational data similarly report chronic pain as a leading motivation for use [16].
Several factors likely contribute to this motivation, such as the burden of long-term pain, opioid risk concerns, perceived stigma or access barriers to pain management, and a perception of kratom as a natural substance.
Safety and Risk Considerations
Although some users report pain relief, kratom carries documented risks. Its reported adverse effects include nausea, constipation, dizziness, dependence and withdrawal symptoms, possible liver injury, and drug interactions.
Analysis of poison control center data shows increasing reports of kratom-related exposures over the past decade [17,18], and in many severe cases, kratom was used alongside other substances.
Unlike regulated pharmaceuticals, kratom products may contain variable alkaloid concentrations, adulterants, heavy metals, or microbial contaminants.
Gaps in the Evidence Base
Despite anecdotal use for chronic pain, major gaps remain in the research literature concerning kratom. To date, there are no large randomized controlled trials in humans evaluating long-term safety, limited dose-response data, insufficient pharmacokinetic profiling in humans, and inconsistent product standardization.
Systematic reviews consistently conclude that current evidence is insufficient to recommend kratom as a safe or effective treatment for pain [12].
Legal and Regulatory Landscape
Kratom’s legal status varies globally. Some countries classify it as a controlled substance, whereas others allow sale with minimal regulation. In the United States, kratom remains federally legal but is restricted or banned in certain states [19].
Regulatory uncertainty reflects ongoing debate regarding its potential therapeutic value versus its abuse liability and public safety concerns [20,21].
Conclusion
Acute pain and chronic pain differ fundamentally in duration, biological mechanisms, and management strategies. Acute pain is typically short-lived and responsive to conventional treatments, whereas chronic pain, by contrast, can persist for months or years and often requires a complex, multimodal approach.
Kratom is most often reported as being used in the context of chronic pain rather than acute pain. Its opioid-receptor activity provides a pharmacological basis for why individuals may perceive relief. Yet robust clinical evidence supporting its safety and effectiveness remains limited, and regulatory agencies continue to express caution on its use.
Until well-controlled clinical trials clarify kratom’s therapeutic potential and risks in humans, evidence-based pain management strategies remain the foundation of care.
References
[1] K.P. Grichnik, F.M. Ferrante, The difference between acute and chronic pain, Mt Sinai J Med 58 (1991) 217–220.
[2] C. Bonezzi, D. Fornasari, C. Cricelli, A. Magni, G. Ventriglia, Not All Pain is Created Equal: Basic Definitions and Diagnostic Work-Up, Pain Ther 9 (2020) 1–15. https://doi.org/10.1007/
[3] R.J. Romanelli, S.N. Shah, L. Ikeda, B. Lynch, T.L. Craig, J.C. Cappelleri, T. Jukes, D. Ishisaka, Patient characteristics and healthcare utilization of a chronic pain population within an integrated healthcare system, Am J Manag Care 23 (2017) e50–e56.
[4] C.J. Mun, L.V. Panlilio, K.E. Dunn, J. Thrul, C.R. McCurdy, D.H. Epstein, K.E. Smith, Kratom (Mitragyna speciosa) use for self-management of pain: Insights from cross-sectional and ecological momentary assessment data, The Journal of Pain 26 (2025) 104726. https://doi.org/10.1016/j.
[5] P. Bialas, C. Maier, P. Klose, W. Häuser, Efficacy and harms of long‐term opioid therapy in chronic non‐cancer pain: Systematic review and meta‐analysis of open‐label extension trials with a study duration ≥26 weeks, European Journal of Pain 24 (2020) 265–278. https://doi.org/10.1002/ejp.
[6] W.C. Prozialeck, J.K. Jivan, S.V. Andurkar, Pharmacology of kratom: an emerging botanical agent with stimulant, analgesic and opioid-like effects, J Am Osteopath Assoc 112 (2012) 792–799.
[7] T. Emerick, S. Durbhakula, M.R. Eibel, L. Kohan, Kratom: a primer for pain physicians, Current Opinion in Anaesthesiology 37 (2024) 575–580. https://doi.org/10.1097/ACO.
[8] L.L. Wilson, S. Chakraborty, S.O. Eans, T.J. Cirino, H.M. Stacy, C.A. Simons, R. Uprety, S. Majumdar, J.P. McLaughlin, Kratom Alkaloids, Natural and Semi-Synthetic, Show Less Physical Dependence and Ameliorate Opioid Withdrawal, Cell Mol Neurobiol 41 (2021) 1131–1143. https://doi.org/10.1007/
[9] C. Michael White, Pharmacologic and clinical assessment of kratom, American Journal of Health-System Pharmacy 75 (2018) 261–267. https://doi.org/10.2146/
[10] J.E. Henningfield, D.W. Wang, M.A. Huestis, Kratom Abuse Potential 2021: An Updated Eight Factor Analysis, Front. Pharmacol. 12 (2022) 775073. https://doi.org/10.3389/fphar.
[11] W.C. Prozialeck, Update on the Pharmacology and Legal Status of Kratom, Journal of Osteopathic Medicine 116 (2016) 802–809. https://doi.org/10.7556/jaoa.
[12] A.C. Kruegel, O. Grundmann, The medicinal chemistry and neuropharmacology of kratom: A preliminary discussion of a promising medicinal plant and analysis of its potential for abuse, Neuropharmacology 134 (2018) 108–120. https://doi.org/10.1016/j.
[13] J.M. Rogers, K. Colvin, D.H. Epstein, O. Grundmann, C.R. McCurdy, K.E. Smith, Growing pains with kratom: experiences discussed in subreddits contrast with satisfaction expressed in surveys, Front. Pharmacol. 15 (2024) 1412397. https://doi.org/10.3389/fphar.
[14] M.A. Coe, J.L. Pillitteri, M.A. Sembower, K.K. Gerlach, J.E. Henningfield, Kratom as a substitute for opioids: Results from an online survey, Drug and Alcohol Dependence 202 (2019) 24–32. https://doi.org/10.1016/j.
[15] K.E. Smith, T. Lawson, Prevalence and motivations for kratom use in a sample of substance users enrolled in a residential treatment program, Drug and Alcohol Dependence 180 (2017) 340–348. https://doi.org/10.1016/j.
[16] O. Grundmann, Patterns of Kratom use and health impact in the US—Results from an online survey, Drug and Alcohol Dependence 176 (2017) 63–70. https://doi.org/10.1016/j.
[17] S. Post, H.A. Spiller, T. Chounthirath, G.A. Smith, Kratom exposures reported to United States poison control centers: 2011–2017, Clinical Toxicology 57 (2019) 847–854. https://doi.org/10.1080/
[18] C.W. Striley, C.C. Hoeflich, A.T. Viegas, L.A. Berkowitz, E.G. Matthews, L.P. Akin, C. Iheanyi-Okeahialam, U. Mansoor, C.R. McCurdy, Health Effects Associated With Kratom ( Mitragyna speciosa ) and Polysubstance Use: A Narrative Review, Subst�Abuse 16 (2022) 11782218221095873. https://doi.org/10.1177/
[19] M.S. Ellis, M.E. Buttram, A. Forber, J.C. Black, Associations Between Kratom-Related State Policy Environments and Kratom Use in a Nationally Representative Population in the United States, Journal of Psychoactive Drugs 56 (2024) 333–341. https://doi.org/10.1080/
[20] W.C. Prozialeck, B.A. Avery, E.W. Boyer, O. Grundmann, J.E. Henningfield, A.C. Kruegel, L.R. McMahon, C.R. McCurdy, M.T. Swogger, C.A. Veltri, D. Singh, Kratom policy: The challenge of balancing therapeutic potential with public safety, International Journal of Drug Policy 70 (2019) 70–77. https://doi.org/10.1016/j.
[21] J.E. Henningfield, R.V. Fant, D.W. Wang, The abuse potential of kratom according the 8 factors of the controlled substances act: implications for regulation and research, Psychopharmacology 235 (2018) 573–589. https://doi.org/10.1007/
